Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Long Non-Coding RNA Sequencing Service market size was valued at USD 772 million in 2024. The market is projected to grow to USD 1313 million by 2031, exhibiting a CAGR of 7.8% during the forecast period. The U.S. market was a significant contributor in 2024, while the Chinese market is anticipated to exhibit substantial growth.
Long Non-Coding RNA (lncRNA) Sequencing Service is a sophisticated Next-Generation Sequencing (NGS)-based molecular biology service. It is designed to comprehensively detect and analyze long non-coding RNAs, which are RNA transcripts longer than 200 nucleotides that do not encode proteins. These lncRNAs are now understood to play crucial regulatory roles in critical biological processes including gene expression, chromatin remodeling, and cellular differentiation, making them vital for research into disease pathogenesis. The service involves a complete workflow from total RNA extraction and ribosomal RNA depletion to the construction of lncRNA-enriched libraries, deep sequencing, and advanced bioinformatics analysis for differential expression profiling and functional annotation.
The market's robust growth is primarily driven by the escalating demand for personalized medicine and the increasing focus on oncology research, where lncRNAs are key biomarkers. Furthermore, continuous advancements in NGS technologies are making these services more accessible and cost-effective. The competitive landscape features key global players such as Novogene, Eurofins Scientific, and BGI, who offer a wide range of service portfolios. While the market is growing, challenges such as the high cost of sophisticated bioinformatics analysis and the need for specialized expertise remain. However, the untapped potential in understanding complex diseases ensures a promising future for this market segment.
Growing Emphasis on Personalized Medicine
The increasing focus on personalized medicine is a primary driver for the long non-coding RNA sequencing service market. lncRNAs are recognized for their crucial roles in gene regulation and disease mechanisms, making them valuable biomarkers for patient stratification and targeted therapies. This demand is particularly strong in oncology, where specific lncRNA signatures can predict treatment response and disease progression.
Technological Advancements in Sequencing Platforms
Continuous innovation in next-generation sequencing technologies, including improvements in throughput, accuracy, and cost-efficiency, is significantly propelling the market. The development of long-read sequencing platforms, such as those from PacBio and Oxford Nanopore, enables more comprehensive and accurate characterization of full-length lncRNA transcripts, which was previously a major technical challenge.
Rising R&D Investment in Functional Genomics
Substantial investment from both public and private sectors into functional genomics research is accelerating the discovery of novel lncRNAs and their functions. Government initiatives, such as grants from the National Institutes of Health, and venture capital funding for biotech startups are directly fueling the demand for specialized sequencing services to validate and characterize these molecules.
MARKET CHALLENGES
Data Analysis and Interpretation Complexity
A significant challenge lies in the bioinformatic analysis of lncRNA sequencing data. Unlike protein-coding genes, lncRNAs are poorly annotated, and their functional analysis requires sophisticated computational pipelines and expertise. This complexity can create a bottleneck for researchers without specialized bioinformatics support, limiting broader adoption of these services.
Other Challenges
High Cost of Service
Despite falling sequencing costs, comprehensive lncRNA sequencing projects, especially those requiring deep sequencing or long-read technologies, remain expensive. This high cost can be a barrier for academic labs and smaller biotech companies with constrained budgets.
Sample Quality and Standardization
The quality of RNA extracted from clinical or biological samples is critical for successful lncRNA sequencing. Issues with RNA degradation, contamination, or a lack of standardized protocols for sample handling can lead to unreliable data, affecting the consistency and reproducibility of results across different service providers.
Regulatory and Reimbursement Hurdles
The translation of lncRNA discoveries into clinically applicable diagnostics faces stringent regulatory pathways. The lack of established guidelines from bodies like the FDA for lncRNA-based tests, combined with uncertain reimbursement policies from healthcare payers, slows down commercial adoption and investment in diagnostic applications, thereby restraining market growth.
Limited Commercial Awareness
While the academic community is highly active in lncRNA research, awareness and understanding of their clinical and commercial potential among pharmaceutical and diagnostic companies are still developing. This knowledge gap can delay the integration of lncRNA analysis into standard drug development pipelines and diagnostic workflows.
Expansion into Non-Oncology Applications
While cancer research dominates current demand, significant opportunities exist in applying lncRNA sequencing to neurological disorders, cardiovascular diseases, and autoimmune conditions. Research is increasingly uncovering the role of lncRNAs in these areas, opening up new, substantial markets for sequencing services beyond oncology.
Development of Integrated Service Offerings
There is a growing opportunity for service providers to differentiate themselves by offering end-to-end solutions. This includes not just sequencing but also comprehensive support for experimental design, advanced bioinformatic analysis, and functional validation of lncRNAs. Such integrated packages provide greater value to clients and create stronger, long-term partnerships.
Emerging Markets and Collaborations
Geographic expansion into emerging markets in Asia-Pacific and Latin America, where biomedical research funding is increasing, presents a key growth avenue. Furthermore, strategic collaborations between sequencing service providers, pharmaceutical companies, and academic institutions can accelerate the development of lncRNA-based therapeutics and diagnostics, creating a larger addressable market.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Strand-Specific Sequencing dominates the market as the preferred methodology due to its superior ability to accurately determine the strand of origin for each transcript. This capability is crucial for lncRNA research, as it enables the correct annotation of antisense transcripts and the precise identification of regulatory mechanisms. The demand for this more sophisticated and informative data output is driven by the increasing complexity of research questions in functional genomics, making it the leading technological approach. |
| By Application |
|
Oncology Research is the most significant application area, fueled by the critical role lncRNAs play in cancer pathogenesis, including tumor suppression, oncogenic processes, and therapy resistance. The continuous discovery of lncRNA biomarkers for diagnosis, prognosis, and as potential therapeutic targets in various cancers creates sustained and high demand for sequencing services from both academic institutions and pharmaceutical companies, making it the largest and fastest-growing application segment. |
| By End User |
|
Academic & Research Institutes represent the core end-user segment, constituting the primary source of fundamental discoveries in lncRNA biology. Their extensive, grant-funded research projects exploring gene regulation and disease mechanisms generate a high volume of service demand. While pharmaceutical companies are a rapidly growing segment due to drug discovery initiatives, the broad-based and foundational research conducted by universities and institutes continues to anchor the market, establishing them as the leading consumer group. |
| By Service Depth |
|
Full Service (Sequencing + Advanced Bioinformatics) is the leading service depth category, as the true value of lncRNA sequencing is unlocked through sophisticated data interpretation. Clients increasingly prefer bundled offerings that provide not just raw data but also comprehensive analyses like novel lncRNA prediction, differential expression, and functional enrichment. This trend is driven by the complexity of lncRNA data and a common lack of in-house bioinformatics expertise among life science researchers, making end-to-end solutions highly desirable. |
| By Sample Type |
|
Human Clinical Samples represent a leading and expanding segment due to the strong translational research focus in lncRNA studies. The direct analysis of patient-derived samples, such as biopsies and blood samples, is essential for validating findings from model systems and discovering clinically relevant lncRNA biomarkers. The growing emphasis on personalized medicine and the need to understand human-specific lncRNA functions are key drivers solidifying the prominence of this sample type in the market. |
A dynamic market with global leaders and specialized niche providers
The competitive landscape of the Long Non-Coding RNA Sequencing Service market is characterized by the dominance of a few large, globally recognized genomics service providers. Novogene, Eurofins Scientific, and BGI are considered the top-tier players, collectively holding a significant revenue share of the global market in 2024. These companies leverage their extensive global infrastructure, high-throughput sequencing capacity, and established bioinformatics pipelines to serve a broad client base across academia, pharmaceutical companies, and biotechnology firms. Their strength lies in offering comprehensive, end-to-end services from sample preparation to advanced data analysis, making them the go-to partners for large-scale research projects requiring robust and reliable data. The market is moderately concentrated, but competition is intensifying as technological advancements make sequencing more accessible.
Beyond the market leaders, a strong cadre of specialized and regional players contributes significantly to the market's dynamism. Companies such as Arraystar distinguish themselves by focusing on specific methodological expertise, like specialized library preparation kits for lncRNA enrichment. Similarly, service providers like LC Sciences and Creative Biolabs offer tailored solutions for specific application areas, such as immunology or oncology research. Emerging players, particularly in the Asia-Pacific region like IGE Biotechnology and Mtoz Biolabs, are gaining traction by offering cost-effective solutions and rapid turnaround times, catering to the growing regional demand. This tier of companies often competes on specialization, customer service, and flexibility, addressing the needs of researchers with more focused or budget-conscious projects.
List of Key Long Non-Coding RNA Sequencing Service Companies ProfiledNovogene
BGI
Arraystar
IGE Biotechnology
Mtoz Biolabs
TIANGEN
GentleGen
Creative Biolabs
Beijing Huaruikang Technology
The global Long Non-Coding RNA (lncRNA) Sequencing Service market is witnessing significant growth, reflecting the increasing recognition of lncRNAs' critical roles in biology and disease. The market, valued at $772 million in 2024, is projected to expand to $1313 million by 2031, achieving a Compound Annual Growth Rate (CAGR) of 7.8%. This expansion is primarily fueled by deep investment in biomedical research, particularly in oncology and immunology. The service is indispensable for identifying novel biomarkers and therapeutic targets by comprehensively profiling lncRNAs, which regulate gene expression and are implicated in diseases like cancer and neurological disorders. The technical process, involving RNA extraction, library preparation, deep sequencing, and sophisticated bioinformatics analysis, delivers critical insights that are not possible with standard coding RNA analysis.
Other TrendsTechnological Segmentation and Regional Dynamics
A key trend within the market is the segmentation by sequencing type, with Strand-Specific Sequencing emerging as a prominent segment due to its ability to accurately determine the strand of origin for transcripts, providing more reliable data for functional annotation. Geographically, the market is led by North America, with the U.S. being a major contributor, while the Asia-Pacific region, especially China, is expected to show the highest growth rate. This regional shift is driven by increasing government and private funding for genomics research and a growing biotechnology sector.
Consolidated Competitive Landscape with Strategic FocusThe competitive environment is characterized by the presence of established global players such as Novogene, Eurofins Scientific, and BGI, which collectively held a significant revenue share in 2024. Competition is intensifying as companies focus on enhancing their bioinformatics capabilities, expanding service portfolios, and forming strategic collaborations with academic and pharmaceutical institutions. The market's growth, however, is tempered by challenges such as the high cost of sequencing services and the need for specialized expertise in data interpretation. Overall, the market trends indicate a trajectory of sustained growth, driven by continuous technological advancements and the expanding application of lncRNA research in personalized medicine and drug discovery.
Regional Analysis: Long Non-Coding RNA Sequencing Service MarketEurope
Europe represents a major and highly sophisticated market for lncRNA sequencing services, characterized by collaborative, multi-national research initiatives and strong national healthcare systems. Countries like the United Kingdom, Germany, and France are at the forefront, boasting world-class research institutions and a significant focus on fundamental biological research. The European market benefits from large-scale, publicly funded projects that often include lncRNA analysis components, creating a steady demand for high-quality sequencing services. The presence of stringent data protection regulations, such as GDPR, influences how sequencing data is handled, prompting service providers to develop robust data security and management solutions. While funding may be more fragmented compared to North America, the collaborative nature of European science, facilitated by entities like the European Molecular Biology Laboratory, fosters a dynamic and innovative market environment.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for lncRNA sequencing services, driven by rapidly expanding biotechnology sectors, increasing government investments in genomics, and a growing focus on precision medicine. China is the dominant force, with massive national genomics initiatives and a booming biotech industry creating immense demand. Japan and South Korea also contribute significantly with their advanced technological capabilities and strong academic research bases. The market growth is further fueled by the rising prevalence of chronic diseases, leading to increased research into lncRNAs as diagnostic and prognostic tools. Cost-competitiveness is a key characteristic, with many service providers offering high-quality sequencing at lower prices, attracting both domestic and international clients. However, the market landscape is more fragmented, with varying levels of regulatory maturity across different countries.
South America
The lncRNA sequencing service market in South America is nascent but showing promising growth, primarily concentrated in research-rich countries like Brazil and Argentina. Market development is driven by increasing awareness of the importance of non-coding RNAs in disease biology and growing collaborations with international research groups. Local academic institutions and public health organizations are the primary consumers of these services, often focusing on regionally prevalent diseases. The market faces challenges related to funding constraints and less developed research infrastructure compared to more mature regions. However, efforts to build local genomic capacity and participate in global research consortia are gradually expanding the market's scope and sophistication.
Middle East & Africa
The Middle East & Africa region presents an emerging opportunity for the lncRNA sequencing service market, with growth largely centered in the Gulf Cooperation Council countries, particularly Saudi Arabia and the UAE. These nations are making strategic investments in building genomic medicine capabilities as part of broader economic diversification and healthcare modernization plans. South Africa also has active research groups utilizing these services. The market is characterized by a strong focus on population-specific genetics and hereditary disorders. A significant portion of the demand is currently met through partnerships with international service providers, but there is a growing trend toward establishing local sequencing and bioinformatics expertise to build a more self-sufficient regional market.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biotechnology and pharmaceutical companies
Academic and research institutions
Healthcare providers
Diagnostic laboratories
Investors, consultants, and policy makers
-> Global long non-coding RNA sequencing service market was valued at USD 772 million in 2024 and is expected to reach USD 1313 million by 2031.
Which key companies operate in Global Long Non-Coding RNA Sequencing Service Market?
-> Key players include Novogene, Eurofins Scientific, BGI, CD Genomics, and Arraystar, among others.
-> Key growth drivers include increasing demand for personalized medicine, advancements in NGS technologies, and growing oncology research.
-> North America is the largest market, while Asia-Pacific is expected to show the highest growth.
-> Emerging trends include increased focus on cancer biomarker discovery and integration of AI in bioinformatics analysis.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates